News Releases

News Category

Year

14 Jun '2021

Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update

ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA ® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in early prostate cancer with

PDF Version

19 May '2021

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCETON, N.J.

PDF Version

28 Apr '2021

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

PRINCETON, N.J. , April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination

PDF Version

26 Apr '2021

UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program PRINCETON, N.J. , April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that

PDF Version

26 Apr '2021

Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Non-dilutive capital to support advancement of ADXS-HOT neoantigen program PRINCETON, N.J. , April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the

PDF Version

12 Apr '2021

Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PRINCETON, N.J. , April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two

PDF Version

10 Apr '2021

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting for both free and drug-bound PD-1 Results

PDF Version

05 Apr '2021

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer

Initiation of Phase 1 study in biochemically recurrent prostate cancer anticipated in Q2 PRINCETON, N.J. , April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

PDF Version

23 Mar '2021

Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

PRINCETON, N.J. , March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis , will

PDF Version

16 Mar '2021

Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update

Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors ADXS-503 Phase 1/2 trial data presented at SITC demonstrated disease control rate of 67% and overall response rate of 17% in first six evaluable

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13